Print

IPCAVD008

A First in Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Dose Levels of Trimeric gp140 Protein in Healthy Adult Volunteers

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID), Crucell Holland BV December 01, 2014
Trimeric gp140 trimeric gp140
Trimeric gp140 Protein
USA 50
NCT02304185
https://clinicaltrials.gov/show/NCT02304185